

ASX ANNOUNCEMENT

27 November 2013

DISTRIBUTION SCHEDULES & TOP HOLDER REPORTS

Distribution - Ordinary Shares

Spread of Holdings	Shareholder	Shares	% of Issued Capital
1 - 1,000	263	127,761	0.23%
1,001 - 5,000	270	756,716	1.38%
5,001 - 10,000	104	849,567	1.55%
10,001 - 100,000	368	11,711,816	21.33%
100,001 - 9,999,999	81	41,460,842	75.51%
TOTAL	1,086	54,906,702	100.00%

Top 20 Shareholders

Rank	Holder Name	Shares	%
1	MR IAN DIXON	2,383,317	4.34%
2	PROFESSOR IGOR SLUKVIN	2,383,317	4.34%
3	CELTIC CAPITAL PTE LTD <TRADING 1 A/C>	2,000,000	3.64%
4	JK NOMINEES PTY LTD<THE JK FUND A/C>	1,993,916	3.63%
5	DENLIN NOMINEES PTY LTD	1,993,916	3.63%
6	TISIA NOMINEES PTY LTD <HENDERSON FAMILY A/C>	1,975,000	3.60%
7	DR ALLEN BOLLANDS	1,787,488	3.26%
8	DR ROGER ASTON	1,787,488	3.26%
9	BANNABY INVESTMENTS PTY LTD <BANNABY SUPER FUND A/C>	1,293,916	2.36%
10	EQUITAS NOMINEES PTY LTD <GROUP A A/C>	1,262,500	2.30%
11	WEBINVEST PTY LTD <OSLB UNIT A/C>	1,250,000	2.28%
12	DR MAKYSM VODYANYK	1,191,658	2.17%
13	INTERSUISSE NOMINEES PTY LTD <CUSTODIAN A/C>	1,181,257	2.15%
14	ARDROY SECURITIES PTY LTD <CAMERON INVESTMENT UNIT A/C>	914,650	1.67%
15	AVIEMORE CAPITAL PTY LTD	750,000	1.37%
16	RYDER CAPITAL PTY LTD	750,000	1.37%
17	MULLOWAY PTY LTD <JOHN HARTLEY POYNTON FM A/C>	650,000	1.18%
18	MULLOWAY PTY LTD <FAMILY A/C>	625,000	1.14%
19	PACIFIC DEVELOPMENT CAPITAL LTD	625,000	1.14%
20	CABLETIME PTY LTD <INGODWE A/C>	625,000	1.14%
		27,423,423	49.97%

Distribution – Listed 31/12/14 Options			
Spread of Holdings	Holders	Options	%
1 - 1,000	63	26,233	0.23
1,001 - 5,000	32	86,867	0.78
5,001 - 10,000	17	123,526	1.11
10,001 - 100,000	38	1,597,859	14.31
100,001 - 9,999,999	20	9,330,216	83.57
TOTAL ON REGISTER	170	11,164,701	100.00

Top 20 Listed 31/12/14 Option Holders

Rank	Holder Name	Options	%
1	TISIA NOMINEES PTY LTD <HENDERSON FAMILY A/C>	1,500,000	13.44%
2	JK NOMINEES PTYLTD <THE JK FUND A/C>	1,500,000	13.44%
3	CELTIC CAP PTE LTD <TRADING 1 A/C>	1,500,000	13.44%
4	DENLIN NOMINEES PTY LTD	1,400,000	12.54%
5	BRIJOHN NOMINEES PTY LTD <NELSONIO A/C>	422,201	3.78%
6	EQUITAS NOMINEES PTY LTD <GROUP A A/C>	411,800	3.69%
7	MR GRANT THOMAS PATERSON <GTP FAMILY A/C>	300,000	2.69%
8	MR PAUL CRAIG STARKIE	275,000	2.46%
9	MS ANNE KOPPE	275,000	2.46%
10	MR JORDAN ROSS BELFORT	275,000	2.46%
11	PLANE SAILING TRAILS PTY LTD <PST SUPER A/C>	200,000	1.79%
12	MR ROBERT W WATERHOUSE	189,500	1.70%
13	MR HOWARD ANDREW DIGBY	187,500	1.68%
14	TEMPO CAPITAL PTY LTD <TEMPO GROWTH FUND A/C>	150,000	1.34%
15	KIRRIEMUIR INVESTMENTS PTY LTD	150,000	1.34%
16	RICKENBACKER CAPITAL INVESTMENTS PTY LTD	150,000	1.34%
17	DENUM ENTERPRISES PTY LTD <NEXT GENERATION SPORTS A/C>	115,159	1.03%
18	PETER KYROS PTY LTD <SUPERANNUATION FUND ACCOUNT>	115,000	1.03%
19	MR CRAIG WILLIAM MANNERS	111,556	1.00%
20	MR PETER GORDON WEBSE	102,500	0.92%
		9,330,216	83.57%

Dr Ross Macdonald

Managing Director & Chief Executive Officer
+61 412 119 343

About Cynata Therapeutics Limited

Cynata Therapeutics Ltd is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.